Molecular subtype changes after acquiring resistance to tarlatamab in small cell lung cancer
Tarlatamab, a novel bispecific T-cell engager, has demonstrated unprecedented efficacy in patients with small cell lung cancer. However, there is no known mechanism of resistance to tarlatamab. This study suggests that a transcriptional expression shift might be associated with acquired resistance to tarlatamab.
Authors
- Jae Min Kim (ORCID: https://orcid.org/0000-0003-4217-3228)
- Hyung‐Min Ahn (ORCID: https://orcid.org/0000-0002-7084-9048)
- Seog-Yun Park
- Yura Choi
- Youngjoo Lee (ORCID: https://orcid.org/0000-0003-0180-189X)
Institutions
- National Cancer Center (US)
- National Cancer Center (KR)
Publication Details
- Journal
- Drug Resistance Updates
- Published
- 2024-12-26
- DOI
- https://doi.org/10.1016/j.drup.2024.101198
- Citations
- 6
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.70
Funders
- National Cancer Center